Pregled bibliografske jedinice broj: 446092
Long-Lasting Control of Triple-Negative Metastatic Breast Cancer with the Novel Drug Combination Ixabepilone and Capecitabin - Case Report
Long-Lasting Control of Triple-Negative Metastatic Breast Cancer with the Novel Drug Combination Ixabepilone and Capecitabin - Case Report // Onkologie, 33 (2010), 1-2; 53-56 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 446092 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Long-Lasting Control of Triple-Negative
Metastatic Breast Cancer with the Novel Drug
Combination Ixabepilone and Capecitabin - Case
Report
Autori
Vrdoljak, Eduard ; Miše Polić, Branka ; Lukić, Blanka ; Curić, Zvonimir ; Bošković, Lidija ; Tica, Ivana
Izvornik
Onkologie (0378-584X) 33
(2010), 1-2;
53-56
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
triple-negative ; breast cancer ; ixabepilone ; capecitabine
Sažetak
The optimal duration of ixabepilone and capecitabine chemotherapy combination is currently not known and will most likely be patient-specific based on efficacy, toxicity, quality of life, and patient preference. Case We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple- negative metastatic breast cancer previously treated with anthracyclines and taxanes. Partial remission was achieved, and acceptable toxicity was observed. This report adds to the pool of knowledge regarding the use of this important new metastatic breast cancer regimen, especially with respect to the optimal duration of its use.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
MZOS-216-0000000-0484 - Dvostruki model ovarijalne kancerogeneze - molekularna i morfološka studija (Tomić, Snježana, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
